Daniel S. Levine
LightNews LightNews
banner
dslevine.bsky.social
Daniel S. Levine
@dslevine.bsky.social
49 followers 38 following 170 posts
Principal, Levine Media Group, host of The Bio Report and RARECast podcasts, award-winning journalist focused on the life sciences.
Posts Replies Media Videos
dslevine.bsky.social
Marc Iacobucci of NanOlogy discusses how the company’s platform technology enables high-concentration dosing inside tumors that destroys cancer cells, stimulates immune responses, and spares patients the debilitating effects of systemic chemotherapy.

thebioreport.podbean.com/e/targeting-...
January 14, 2026 at 4:58 PM
dslevine.bsky.social
BioUsawa announced a regulatory milestone in its mission to democratize access to high-quality, affordable biologic therapies across Africa with approval in Ghana of biosimilar to Lucentis.
www.globenewswire.com/news-release...
Bio Usawa Receives Ghana FDA Approval for BioUcenta™
Ghana follows Rwanda in approving BioUcenta™, Africa’s first approved ranibizumab biosimilar...
www.globenewswire.com
January 13, 2026 at 7:10 PM
dslevine.bsky.social
Allison Hulme, CEO of Aeovian Pharmaceuticals, discusses tuberous sclerosis complex, the problems with existing therapies; and the opportunity for its next-generation, selective mTOR inhibitors to treat TSC and beyond. @globalgenes.bsky.social #RARECast

globalgenes.org/raredaily/tr...
Transforming TSC Epilepsy with a Precision Therapy
Allison Hulme, CEO of Aeovian Pharmaceuticals, discusses tuberous sclerosis complex, the problems with existing therapies for seizures related to the condition, and the opportunity for its next-genera...
globalgenes.org
January 9, 2026 at 5:39 PM
dslevine.bsky.social
Valerie Daggett, CEO of AltPep, discusses the relationship between α-sheet oligomers and the onset of Alzheimer’s disease, the company’s synthetic peptides to target them, and the potential for its platform to treat a broader set of amyloid diseases.

thebioreport.podbean.com/e/an-effort-...
January 7, 2026 at 6:15 PM
dslevine.bsky.social
Matt Wood @oxfordharrington.bsky.social discusses the challenges of rare disease drug development, the resources the center brings to address them, and the mechanisms it has established to accelerate therapeutic development. @globalgenes.bsky.social #RARECast

globalgenes.org?post_type=ra...
January 5, 2026 at 4:30 PM
dslevine.bsky.social
Adam Feuerstein, senior biotech writer for STAT, joins us for our annual review-preview edition to discuss the noteworthy trends in the biotech sector in 2025, and what’s in store at the upcoming JPMorgan Healthcare Conference and beyond in 2026.

thebioreport.podbean.com/e/the-year-i...
December 31, 2025 at 4:37 PM
dslevine.bsky.social
Floyd and Monique Stewart discuss navigating the healthcare system with a rare cancer diagnosis, the strain the experience put on their family, and why today they are rare disease advocates for families dealing with similar problems. @globalgenes.bsky.social #RARECast
globalgenes.org/raredaily/tu...
Turning a Rare Cancer into a Call to Action
Floyd and Monique Stewart discuss how they navigated the healthcare system after Floyd's diagnosis with a rare cancer, the strain the experience put on their family, and why today they are rare diseas...
globalgenes.org
December 26, 2025 at 4:16 PM
dslevine.bsky.social
Adam Gridley, CEO of Allay Therapeutics, discusses post-surgical pain, the need for alternatives to opioids, and the company’s experimental, implanted, extended-release analgesic.
thebioreport.podbean.com/e/developing...
December 24, 2025 at 5:01 PM
dslevine.bsky.social
Mike Cloonan, CEO of Sionna, discusses the company’s experimental therapy that stabilizes the misfolded protein at the heart of cystic fibrosis, its exploration of combinations with existing and proprietary therapies, and its $219M IPO. @globalgenes.bsky.social

globalgenes.org/raredaily/de...
Developing a New Approach to Cystic Fibrosis to Improve Outcomes
Mike Cloonan, CEO of Sionna, discusses its experimental therapy that stabilizes the misfolded protein at the heart of the disease, its exploration of combination therapies with existing and proprietar...
globalgenes.org
December 19, 2025 at 4:38 PM
dslevine.bsky.social
Kang Hsu, CMO of Canary Speech, discusses how its diagnostic tool works to diagnose neurological and psychiatric conditions using vocal biomarkers, how it is embedded invisibly into clinical workflows, and how the company is driving physician adoption.

thebioreport.podbean.com/e/leveraging...
December 17, 2025 at 3:29 PM
dslevine.bsky.social
Tim Sweeney, CEO of Inflammatix, Inc., discusses the company’s point-of-care test for sepsis, how it works; and how it is used in an ER setting to determine who needs antibiotics, ICU‑level care, or a broader diagnostic workup.​

thebioreport.podbean.com/e/determinin...
December 10, 2025 at 3:07 PM
dslevine.bsky.social
Benjamin Zimmer, CEO of Priovant, discusses the company's experimental targeted therapy to treat the rare autoimmune condition dermatomyositis and how its relationship with its parent Roivant frees it from reliance on the capital markets. @globalgenes.bsky.social

globalgenes.org/raredaily/de...
Developing Targeted Therapies for a Rare Autoimmune Disease
Ben Zimmer, CEO of Priovant, discusses the company's experimental targeted therapy to treat the rare autoimmune condition dermatomyositis, how its relationship with its parent Roivant frees it from re...
globalgenes.org
December 5, 2025 at 3:53 PM
dslevine.bsky.social
Atta Behfar, co-founder and CEO of Rion, discusses how the company’s purified exosome products work, their potential as scalable and cost-effective regenerative therapies, and how they avoid the immune issues that have long hampered cell-based approaches.

thebioreport.podbean.com/e/separating...
December 3, 2025 at 3:32 PM
dslevine.bsky.social
Here's what you may have missed in November from The Bio Report, RARECast, and Life Sciences D'n'A podcasts.

www.linkedin.com/pulse/rewrit...
Rewriting Drug Discovery, a Venture Fund that Leverages Patient Experts, and Creating Regulatory Documents with AI
Here's what you may have missed in November from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. The Bio Report Rewriting Drug Discovery with an AI-Multi-Omics Approach The genomics revolu...
www.linkedin.com
December 1, 2025 at 5:25 PM
dslevine.bsky.social
Steven St. Peter, M.D., co-founder and managing director of Vie Ventures, discusses the firm’s investment model, its initial focus on immune-mediated diseases, and its work with major patient organizations. @globalgenes.bsky.social #RARECast

globalgenes.org/raredaily/a-...
A Venture Fund that Leverages Patient Experts to Target Autoimmune Diseases
Steven St. Peter, co-founder and managing director of Vie Ventures, discusses the firm’s investment model, its initial focus on immune-mediated diseases, and its work with major patient organizations.
globalgenes.org
November 28, 2025 at 5:45 PM
dslevine.bsky.social
Anita Modi, CEO and founder of Peer AI, discusses the cultural challenges of integrating AI into a traditionally cautious industry, the need for change management, and why it’s critical to embed human judgment alongside machine intelligence.

www.agilisium.com/podcast/agen...
Agents of Change: Creating Regulatory Documents with AI
In this episode of Life Sciences DNA, Srivatsan Nagaraja speaks with Anita Modi, Founder and CEO of Peer AI, about how agentic AI is reshaping the creation of regulatory and clinical documents across ...
www.agilisium.com
November 27, 2025 at 5:45 PM
dslevine.bsky.social
Mo Jain, chief scientific officer of Sapient, discusses how its technology bridges the gap from discovery to clinical development, accelerates drug development timelines, and expands opportunities to drug previously undruggable targets.

thebioreport.podbean.com/e/rewriting-...
November 26, 2025 at 3:58 PM
dslevine.bsky.social
Nikki McIntosh, author of “Rare Mamas: Empowering Strategies for Navigating Your Child’s Rare Disease,” discusses her new book, the challenges faced by rare disease families, and the importance of making time for self-care. @globalgenes.bsky.social #RARECast

globalgenes.org/raredaily/na...
Navigating Your Child’s Rare Disease
Nikki McIntosh, author of “Rare Mamas: Empowering Strategies for Navigating Your Child’s Rare Disease,” discusses her new book, the medical, emotional, and logistical challenges faced by rare disease ...
globalgenes.org
November 21, 2025 at 3:56 PM
dslevine.bsky.social
Dan Schmitt, CEO of Actuate Therapeutics, discusses the company’s experimental therapy elraglusib’s potential to overcome chemoresistance, its recent clinical successes in metastatic pancreatic cancer, and the drug’s unique multimodal mechanism.

thebioreport.podbean.com/e/overcoming...
November 19, 2025 at 4:45 PM
dslevine.bsky.social
Andrew Rosen @ataxiafoundation.bsky.social, discusses the critical role of patient-led organizations in early-stage research and advocacy, and the recent surge of therapeutic activity targeting these neurodegenerative conditions. @globalgenes.bsky.social #RARECast

globalgenes.org/raredaily/ch...
Changing a Treatment Landscape by De-Risking Drug Development
Andrew Rosen, CEO of the National Ataxia Foundation, discusses the challenges of developing therapies for spinocerebellar ataxia, the critical role of patient-led organizations in early-stage research...
globalgenes.org
November 14, 2025 at 5:02 PM
dslevine.bsky.social
Ronel Veksler, co-founder and CEO of PromiseBio discusses his company’s AI-enabled proteomics platform, and how post-translational modifications of proteins represent a new frontier for precision medicine in autoimmune diseases. www.youtube.com/watch?v=jeJh...
Redefining Biomarkers for Immune-Mediated Disease with AI
YouTube video by Life Sciences DNA Podcast
www.youtube.com
November 13, 2025 at 7:02 PM
dslevine.bsky.social
Theresa Heah, CEO of Eyexora, discusses the hub-and-spoke business model, the company’s initial assets in-licensed from the Singapore Eye Research Institute, and how it identifies early-stage candidates with high potential.

thebioreport.podbean.com/e/a-hub-and-...
November 12, 2025 at 2:56 PM
dslevine.bsky.social
Jeffrey Brown CSO of TriNetX, discusses how real-world data can address common challenges in rare disease research, the hurdles that need to be addressed, and how advances in AI could revolutionize rare disease research. @globalgenes.bsky.social #RARECast

globalgenes.org/raredaily/tr...
Transforming Real-Word Patient Data into Breakthroughs
Jeff Brown, chief scientific officer of TriNetX, discusses how real-world data can address common challenges in rare disease research, the hurdles that need to be addressed, and how advances in AI cou...
globalgenes.org
November 7, 2025 at 5:15 PM
dslevine.bsky.social
Brian Weitzner, co-founder of OpenFold, discusses the collaborative effort to develop software and AI tools to predict the 3D structure of proteins, how its open licensing model ensures broad accessibility, and how it stacks up against AlphaFold.

thebioreport.podbean.com/e/an-ai-coll...
November 5, 2025 at 3:24 PM
dslevine.bsky.social
Here's what you may have missed in October from The Bio Report, RARECast, and Life Sciences D'n'A podcasts.
www.linkedin.com/pulse/why-us...
Why the U.S. Must Fall in Love with Biotech, Rare Disease Advocates Push FDA for Timely Reviews, and Driving Insights from Real-World Data and AI
Here's what you may have missed in October from The Bio Report, RARECast, and Life Sciences D'n'A podcasts. The Bio Report Hitting the Reset Button on Cellular Aging Transcription factors control the ...
www.linkedin.com
November 3, 2025 at 8:51 PM